1. What Does the Future Hold and What Will It Mean for Patients?

3. The Standard of Care is Changing Again

4. Why Do We Need a New Standard of Care?

5. The Ideal Treatment for Chronic HCV Infection

6. Agents in Phase 3 HCV Treatment Pipeline Not Approved for Use in the US

7. Sofosbuvir

8. VALENCE: Sofosbuvir + RBV for 24 Weeks in G3 HCV Infection

9. NEUTRINO Study: SVR12 by HCV Genotype

10. NEUTRINO Study: Virologic Response by Cirrhosis Status

11. Simeprevir in Patients With G1 HCV Infection

12. Shortened Therapy in 85% to 91%

13. Q80K: A Major Issue

14. On the Road to IFN-free Therapy

15. On the Road to IFN-free Therapy (cont)

16. One Size Fits All vs Tailored Regimen

17. Second-Generation Protease Inhibitor-based, IFN-free Regimens

18. PI + NS5A in Prior Null Responders

19. IFN-free Regimens Combining 3 DAA Drug Classes

21. More Potent Protease Inhibitors in Phase 2 Clinical Trials

22. What Does It Mean for Patients?

23. Abbreviations

24. Abbreviations (cont)

25. References

26. References (cont)

27. References (cont)